If you would like to learn more about future focusIR related events and roundtables, please submit your details here

Less Ads, More Data, More Tools Register for FREE

Pin to quick picksIQ-AI Regulatory News (IQAI)

  • There is currently no data for IQAI

Total Voting Rights

28 Feb 2022 11:12

RNS Number : 0358D
IQ-AI Limited
28 February 2022
 

28 February 2022

IQ-AI Ltd

("IQ-AI" or the "Company")

 

Total Voting Rights

 

In accordance with the Financial Conduct Authority's Disclosure and Transparency Rules, IQ-AI announces that the Company has 182,621,390 ordinary shares of 1p each in issue, none of which are held in treasury. Therefore, the total number of voting rights in the Company is 182,621,390.

 

This figure of 182,621,390 may be used by shareholders in the Company as the denominator for the calculations by which they will determine if they are required to notify their interest in, or a change to their interest in, the share capital of the Company under the FCA's Disclosure and Transparency Rules.

 

The Directors of the Company accept responsibility for the contents of this announcement

 

-ENDS-

 

For further information, please contact:

IQ-AI Limited

Trevor Brown/Brett Skelly/Vinod Kaushal

Tel: 020 7469 0930

 

Peterhouse Capital Limited (Financial Adviser and Broker)

Lucy Williams/Heena Karani

Tel: 020 7220 9797

 

Market Abuse Regulation (MAR) Disclosure

This announcement contains inside information for the purposes of Article 7 of the Market Abuse Regulation EU 596/2014 as it forms part of retained EU law (as defined in the European Union (Withdrawal) Act 2018).

This information is provided by RNS, the news service of the London Stock Exchange. RNS is approved by the Financial Conduct Authority to act as a Primary Information Provider in the United Kingdom. Terms and conditions relating to the use and distribution of this information may apply. For further information, please contact rns@lseg.com or visit www.rns.com.RNS may use your IP address to confirm compliance with the terms and conditions, to analyse how you engage with the information contained in this communication, and to share such analysis on an anonymised basis with others as part of our commercial services. For further information about how RNS and the London Stock Exchange use the personal data you provide us, please see our Privacy Policy.
 
END
 
 
TVRBKFBDDBKDDBB
Date   Source Headline
2nd Sep 20217:00 amRNSBoard Changes
1st Sep 202110:00 amRNSStart of Trading on the OTCQB Venture Market
27th Aug 20219:57 amRNSHalf Yearly Report
11th Jun 20214:41 pmRNSSecond Price Monitoring Extn
11th Jun 20214:36 pmRNSPrice Monitoring Extension
11th Jun 20212:05 pmRNSSecond Price Monitoring Extn
11th Jun 20212:00 pmRNSPrice Monitoring Extension
11th Jun 202111:05 amRNSSecond Price Monitoring Extn
11th Jun 202111:00 amRNSPrice Monitoring Extension
11th Jun 20218:00 amRNSIQAI Awarded “Gad-Free” Patent
4th Jun 20217:00 amRNSIB Software Chosen by LA County Hospital
19th May 202112:06 pmRNSResult of AGM
27th Apr 20213:27 pmRNSNotice of AGM
20th Apr 202110:21 amRNSFinal Results
16th Apr 20214:41 pmRNSSecond Price Monitoring Extn
16th Apr 20214:36 pmRNSPrice Monitoring Extension
13th Apr 20217:27 amRNSIQAI commits to Phase 1 study
6th Apr 20217:00 amRNSFive Year NCI Award Grant to IB
5th Feb 20214:41 pmRNSSecond Price Monitoring Extn
5th Feb 20214:36 pmRNSPrice Monitoring Extension
5th Feb 20212:05 pmRNSSecond Price Monitoring Extn
5th Feb 20212:01 pmRNSPrice Monitoring Extension
5th Feb 20219:05 amRNSSecond Price Monitoring Extn
5th Feb 20219:00 amRNSPrice Monitoring Extension
28th Jan 20217:00 amRNS"Gad Free" Imaging Update
25th Jan 202111:01 amRNSPrice Monitoring Extension
14th Jan 20217:00 amRNSTechnology Portfolio Update
7th Jan 20212:06 pmRNSSecond Price Monitoring Extn
7th Jan 20212:00 pmRNSPrice Monitoring Extension
31st Dec 202012:41 pmRNSSecond Price Monitoring Extn
31st Dec 202012:36 pmRNSPrice Monitoring Extension
31st Dec 202011:00 amRNSPrice Monitoring Extension
10th Dec 202010:41 amRNSDirector Dealing and CLN Conversion - Correction
9th Dec 20202:05 pmRNSSecond Price Monitoring Extn
9th Dec 20202:01 pmRNSPrice Monitoring Extension
9th Dec 20209:02 amRNSDirector Dealing and Conversion of Loan Notes
7th Dec 202011:25 amRNSDirector Dealing
4th Dec 20204:52 pmRNSIssue of shares to Mayo Clinic
3rd Dec 20207:01 amRNSRelease of StoneChecker 20.12
26th Nov 20207:00 amRNSIMAGING BIOMETRICS UPGRADES IB CLINIC™ SOFTWARE
23rd Nov 20204:41 pmRNSSecond Price Monitoring Extn
23rd Nov 20204:36 pmRNSPrice Monitoring Extension
23rd Nov 20202:06 pmRNSSecond Price Monitoring Extn
23rd Nov 20202:00 pmRNSPrice Monitoring Extension
23rd Nov 20201:45 pmRNSLSN Software is now CE Mark Approved
23rd Nov 202011:06 amRNSSecond Price Monitoring Extn
23rd Nov 202011:00 amRNSPrice Monitoring Extension
20th Nov 202011:05 amRNSSecond Price Monitoring Extn
20th Nov 202011:00 amRNSPrice Monitoring Extension
20th Nov 20209:05 amRNSSecond Price Monitoring Extn

Due to London Stock Exchange licensing terms, we stipulate that you must be a private investor. We apologise for the inconvenience.

To access our Live RNS you must confirm you are a private investor by using the button below.